The results, which have been published Annals of Neurology, are from two studies over two years designed to asses the relationship between disease activity and health-related quality-of-life (HRQoL) in relapsing forms of MS, and the impact of Tysabri on these measures.
“These data showed that patients treated with Tysabri were more likely to experience statistically important improvement in the quality-of-life measures used to assess meaningful disease improvement or progression. These findings have not been previously observed in clinical studies involving MS patients,” said Richard Rudick, director of the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, the lead investigator of the study.